Novel systemic treatment for hepatocellular carcinoma: a step-by-step review of current indications

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and main cause of cancer-related death worldwide. The available treatment options for HCC include transplant, locoregional therapy (such as ablation, embolization, radiotherapy), systemic treatment. latter encompasses targeted therapy, immunotherapy, angiogenesis inhibitors, alone or in combination. introduction immune checkpoint inhibitors drug has been one significant advances These therapies were shown to prolong overall survival progression-free clinical trials including patients with advanced HCC. In recent years, vastly improved, a median 19.2 months IMbrave150 trial. However, further research needed determine optimal sequence